The David Scheinberg Lab

The overall goals of this laboratory are to develop novel targeted immunotherapies based on effectors of the immune system and to understand their mechanisms of action as well as the mechanisms of resistance to them. This includes antibodies, targeted nano-devices, and active specific agents such vaccines. An important goal is to take these new therapies into human clinical trials for testing. We developed a molecular nanogenerator that releases alpha particles inside cancer cells, now being tested in humans. Read full article in Science (Science, 2001) and a WT1 vaccine, also in national trials (Blood, 2010.) 

We have developed targeted alpha particle therapies, targeted beta emitters, oncogenic protein peptide vaccines, each of which reached human clinical trials; More recently we have discovered TCR mimic antibodies to intracellular proteins (Science Trans. Med., 2013,) as well as prototype targeted nano-machines (Nature Nano, 2013)

David Scheinberg

David A. Scheinberg, MD, PhD

Chair, Molecular Pharmacology Program, SKI; Director, Center for Experimental Therapeutics


Research Focus

Molecular Pharmacology Program Chair David Scheinberg focuses on the discovery and development of novel, specific immunotherapeutic agents and targeted nanodevices for cancer therapy.


MD, PhD, Johns Hopkins University School of Medicine

Research Projects

Learn more